Publication
Article
Author(s):
Pharmacists can learn about current treatment strategies for the management of benign prostatic hyperplasia, including special considerations in managing comorbidities.
Shilpa Amara, PharmD
Drug Information Specialist
Barnabas Health
West Orange, New Jersey
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.
Faculty
Shilpa Amara, PharmD
Pharmacy Times Office of Continuing Professional Education
Planning Staff—Judy V. Lum, MPA, and Steve Lin, PharmD
Pharmacy Times Editorial Staff
Kirk McKay and David Allikas
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
LEARNING Objectives:
Upon completion of this educational activity, participants should be able to:
Target audience: Pharmacists
Type of activity: Knowledge
Release date: November 12, 2013
Expiration date: November 12, 2015
Estimated time to complete activity: 2 hours
Click here to view this activity.
This activity is supported by an educational grant from Watson Laboratories, Inc.
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-13-159-H01-P. The activity is available for CE credit through November 12, 2015.